Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?

Molecular Immunology

Volumn 56, Issue 4, 2013, Pages 660-674

  Gurbaxani, Brian ^a   Dostalek, Miroslav ^b   Gardner, Iain ^c  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

Endosome; Half life; Modelling; Monoclonal antibody; Neonatal Fc receptor; Pharmacokinetics; Trafficking

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; PROTEIN BINDING;

BINDING AFFINITY; CELL MIGRATION; CELL SURFACE; ENDOCYTOSIS; ENDOSOME; ENDOTHELIUM CELL; EXOCYTOSIS; HALF LIFE TIME; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECYCLING; REVIEW; ANTIBODY AFFINITY; BINDING COMPETITION; BIOLOGICAL MODEL; IMMUNOLOGY; METABOLISM; PROTEIN TRANSPORT;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BINDING, COMPETITIVE; ENDOSOMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, FC;

EID: 84881107497     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.05.008     Document Type: Review

References (116)

1. Akilesh S., Christianson G.J., Roopenian D.C., Shaw A.S. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. Journal of Immunology 2007, 179:4580-4588.
2. Antohe F., Radulescu L., Gafencu A., Ghetie V., Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Human Immunology 2001, 62:93-105.
3. Baxter L.T., Zhu H., Mackensen D.G., Jain R.K. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Research 1994, 54:1517-1528.
4. Baxter L.T., Zhu H., Mackensen D.G., Butler W.F., Jain R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Research 1995, 55:4611-4622.
5. Berg H.C., Purcell E.M. Physics of chemoreception. Biophysical Journal 1977, 20:193-219.
6. Berryman M., Rodewald R. Beta 2-microglobulin co-distributes with the heavy chain of the intestinal IgG-Fc receptor throughout the transepithelial transport pathway of the neonatal rat. Journal of Cell Science 1995, 108(Pt 6):2347-2360.
7. Borvak J., Richardson J., Medesan C., Antohe F., Radu C., Simionescu M., Ghetie V., Ward E.S. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. International Immunology 1998, 10:1289-1298.
8. Boswell C.A., Tesar D.B., Mukhyala K., Theil F.P., Fielder P.J., Khawli L.A. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chemistry 2010, 21:2153-2163.
9. Brambell F.W., Hemmings W.A., Morris I.G. A theoretical model of gamma-globulin catabolism. Nature 1964, 203:1352-1354.
10. Cauza K., Hinterhuber G., Dingelmaier-Hovorka R., Brugger K., Klosner G., Horvat R., Wolff K., Foedinger D. Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes. Journal of Investigative Dermatology 2005, 124:132-139.
11. Chabot J.R., Dettling D.E., Jasper P.J., Gomes B.C. Comprehensive mechanism-based antibody pharmacokinetic modeling. Conference Proceeding: IEEE Engineering in Medicine and Biology Society 2011, 4318-4323.
12. Charman S.A., Segrave A.M., Edwards G.A., Porter C.J. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. Journal of Pharmaceutical Sciences 2000, 89:168-177.
13. Chen Y., Balthasar J.P. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. The AAPS Journal 2012, 14:850-859.
14. Chen N., Wang W., Faulty S., Fang Y., Lu P., Hamuro L., Hussain A., Prueksaritanant T. The impact of FcRn on tissue distribution of IgG1 in mice. AAPS 2012.
15. Cianga P., Cianga C., Cozma L., Ward E.S., Carasevici E. The MHC class I related Fc receptor, FcRn, is expressed in the epithelial cells of the human mammary gland. Human Immunology 2003, 64:1152-1159.
16. Claypool S.M., Dickinson B.L., Wagner J.S., Johansen F.E., Venu N., Borawski J.A., Lencer W.I., Blumberg R.S. Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fc gamma-receptor. Molecular Biology of the Cell 2004, 15:1746-1759.
17. Cornillie F., Shealy D., D'Haens G., Geboes K., Van Assche G., Ceuppens J., Wagner C., Schaible T., Plevy S.E., Targan S.R., Rutgeerts P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics 2001, 15:463-473.
18. Covell D.G., Barbet J., Holton O.D., Black C.D., Parker R.J., Weinstein J.N. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Research 1986, 46:3969-3978.
19. Dall'Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., Wu H., Kiener P.A., Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. Journal of Immunology 2002, 169:5171-5180.
20. Dall'Acqua W.F., Kiener P.A., Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). The Journal of Biological Chemistry 2006, 281:23514-23524.
21. Datta-Mannan A., Witcher D.R., Tang Y., Watkins J., Jiang W., Wroblewski V.J. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metabolism and Disposition 2007, 35:86-94.
22. Datta-Mannan A., Witcher D.R., Tang Y., Watkins J., Wroblewski V.J. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. The Journal of Biological Chemistry 2007, 282:1709-1717.
23. Datta-Mannan A., Chow C.K., Dickinson C., Driver D., Lu J., Witcher D.R., Wroblewski V.J. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metabolism and Disposition 2012, 40(8):1545-1555. 10.1124/dmd.112.045864dmd.112.045864 [pii].
24. Datta-Mannan A., Chow C.K., Dickinson C., Driver D., Lu J., Witcher D.R., Wroblewski V.J. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug metabolism and disposition: the biological fate of chemicals 2012, 40:1545-1555.
25. Dean G.S., Pusztai L., Xu F.J., O'Briant K., DeSombre K., Conaway M., Boyer C.M., Mendelsohn J., Bast R.C. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clinical Cancer Research 1998, 4:2545-2550.
26. Deng R., Balthasar J.P. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. Journal of Pharmaceutical Sciences 2007, 96:1625-1637.
27. Deng R., Loyet K.M., Lien S., Iyer S., DeForge L.E., Theil F.P., Lowman H.B., Fielder P.J., Prabhu S. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metabolism and Disposition: the Biological Fate of Chemicals 2010, 38:600-605.
28. Dzidic A., Mohr A., Meyer K., Bauer J., Meyer H.H., Pfaffl M.W. Effects of mycophenolic acid (MPA) treatment on expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA in adult sheep tissues. Croatian Medical Journal 2004, 45:130-135.
29. Ferl G.Z., Wu A.M., DiStefano J.J. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Annals of Biomedical Engineering 2005, 33:1640-1652.
30. Ferl G.Z., Kenanova V., Wu A.M., DiStefano J.J. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Molecular Cancer Therapeutics 2006, 5:1550-1558.
31. Garg A. Investigation of the role of FcRn in the absorption, distribution, and elimination of monoclonal antibodies 2007, Department of Pharmaceutical Sciences, Faculty of the Graduate School of State University of New York at Buffalo, New York, (Ph.D. thesis).
32. Garg A., Balthasar J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. Journal of Pharmacokinetics and Pharmacodynamics 2007, 34:687-709.
33. Getman K.E., Balthasar J.P. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. Journal of Pharmaceutical Sciences 2005, 94:718-729.
34. Ghetie V., Hubbard J.G., Kim J.K., Tsen M.F., Lee Y., Ward E.S. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. European Journal of Immunology 1996, 26:690-696.
35. Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Medesan C., Ober R.J., Ward E.S. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnology 1997, 15:637-640.
36. Goebl N.A., Babbey C.M., Datta-Mannan A., Witcher D.R., Wroblewski V.J., Dunn K.W. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Molecular Biology of the Cell 2008, 19:5490-5505.
37. Gruenberg J. The endocytic pathway: a mosaic of domains. Nature Reviews. Molecular Cell Biology 2001, 2:721-730.
38. Gurbaxani B. Mathematical modeling as accounting: predicting the fate of serum proteins and therapeutic monoclonal antibodies. Clinical Immunology 2007, 122:121-124.
39. Gurbaxani B.M., Morrison S.L. Development of new models for the analysis of Fc-FcRn interactions. Mol Immunol 2006, 43:1379-1389.
40. Gurbaxani B., Dela Cruz L.L., Chintalacharuvu K., Morrison S.L. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Molecular Immunology 2006, 43:1462-1473.
41. Guyton A.C., Hall J.E. Textbook of medical physiology (Guyton physiology). Saunders 2000.
42. Haigler H.T., McKanna J.A., Cohen S. Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. Journal of Cell Biology 1979, 83:82-90.
43. Hansen R.J., Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002, 100:2087-2093.
44. Hansen R.J., Balthasar J.P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thrombosis and Haemostasis 2002, 88:898-899.
45. Hansen R.J., Balthasar J.P. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. Journal of Pharmaceutical Science 2003, 92:1206-1215.
46. Haymann J.P., Levraud J.P., Bouet S., Kappes V., Hagege J., Nguyen G., Xu Y., Rondeau E., Sraer J.D. Characterization and localization of the neonatal Fc receptor in adult human kidney. Journal of the American Society of Nephrology 2000, 11:632-639.
47. Hinton P.R., Johlfs M.G., Xiong J.M., Hanestad K., Ong K.C., Bullock C., Keller S., Tang M.T., Tso J.Y., Vasquez M., Tsurushita N. Engineered human IgG antibodies with longer serum half-lives in primates. The Journal of Biological Chemistry 2004, 279:6213-6216.
48. Hinton P.R., Xiong J.M., Johlfs M.G., Tang M.T., Keller S., Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. Journal of Immunology 2006, 176:346-356.
49. Hopkins C.R., Trowbridge I.S. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. The Journal of Cell Biology 1983, 97:508-521.
50. Igawa T., Tsunoda H., Tachibana T., Maeda A., Mimoto F., Moriyama C., Nanami M., Sekimori Y., Nabuchi Y., Aso Y., Hattori K. Reduced elimination of IgG antibodies by engineering the variable region. Protein Engineering Design and Selection 2010, 23:385-392.
51. Israel E.J., Wilsker D.F., Hayes K.C., Schoenfeld D., Simister N.E. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996, 89:573-578.
52. Jovic M., Sharma M., Rahajeng J., Caplan S. The early endosome: a busy sorting station for proteins at the crossroads. Histology and Histopathology 2010, 25:99-112.
53. Junghans R.P., Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:5512-5516.
54. Kaja S., Hilgenberg J.D., Everett E., Olitsky S.E., Gossage J., Koulen P. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Human Antibodies 2011, 20:95-101.
55. Kobayashi N., Suzuki Y., Tsuge T., Okumura K., Ra C., Tomino Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. American Journal of Physiology Renal Physiology 2002, 282:F358-F365.
56. Kuo T.T., Baker K., Yoshida M., Qiao S.W., Aveson V.G., Lencer W.I., Blumberg R.S. Neonatal Fc receptor: from immunity to therapeutics. Journal of Clinical Immunology 2010, 30:777-789.
57. Lee K.Y., Lee J.S. Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. Medical Hypotheses 2006, 67:848-855.
58. Lencer W.I., Blumberg R.S. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends in Cell Biology 2005, 15:5-9.
59. Lodish H., Baltimore D., Berk A., Zipursky S.L., Matsudaira P., Darnell J. Molecular Cell Biology 1995, Scientific American Books, W.H. Freeman and Company, New York.
60. Lovdal T., Andersen E., Brech A., Berg T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. Journal of Cell Science 2000, 113(Pt 18):3255-3266.
61. Luzio J.P., Gray S.R., Bright N.A. Endosome-lysosome fusion. Biochemical Society Transactions 2010, 38:1413-1416.
62. Martin W.L., West A.P., Gan L., Bjorkman P.J. Crystal structure at 2.8A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Molecular Cell 2001, 7:867-877.
63. Maxfield F.R., McGraw T.E. Endocytic recycling. Nature Reviews Molecular Cell Biology 2004, 5:121-132.
64. McCarthy K.M., Yoong Y., Simister N.E. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. Journal of Cell Science 2000, 113(Pt 7):1277-1285.
65. Medesan C., Matesoi D., Radu C., Ghetie V., Ward E.S. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. Journal of Immunology 1997, 158:2211-2217.
66. Medesan C., Cianga P., Mummert M., Stanescu D., Ghetie V., Ward E.S. Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site. European Journal of Immunology 1998, 28:2092-2100.
67. Mezo A.R., McDonnell K.A., Hehir C.A., Low S.C., Palombella V.J., Stattel J.M., Kamphaus G.D., Fraley C., Zhang Y., Dumont J.A., Bitonti A.J. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2337-2342.
68. Montano R.F., Morrison S.L. Influence of the isotype of the light chain on the properties of IgG. Journal of Immunology 2002, 168:224-231.
69. Ober R.J., Martinez C., Lai X., Zhou J., Ward E.S. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:11076-11081.
70. Ober R.J., Martinez C., Vaccaro C., Zhou J., Ward E.S. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. Journal of Immunology 2004, 172:2021-2029.
71. Petkova S.B., Akilesh S., Sproule T.J., Christianson G.J., Al Khabbaz H., Brown A.C., Presta L.G., Meng Y.G., Roopenian D.C. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. International Immunology 2006, 18:1759-1769.
72. Platta H.W., Stenmark H. Endocytosis and signaling. Current Opinion in Cell Biology 2011, 23:393-403.
73. Popov S., Hubbard J.G., Kim J., Ober B., Ghetie V., Ward E.S. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Molecular Immunology 1996, 33:521-530.
74. Porter C.J., Charman S.A. Lymphatic transport of proteins after subcutaneous administration. Journal of Pharmaceutical Science 2000, 89:297-310.
75. Raghavan M., Bjorkman P.J. Fc receptors and their interactions with immunoglobulins. Annual Review of Cell and Developmental Biology 1996, 12:181-220.
76. Raghavan M., Gastinel L.N., Bjorkman P.J. The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 1993, 32:8654-8660.
77. Raghavan M., Chen M.Y., Gastinel L.N., Bjorkman P.J. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1994, 1:303-315.
78. Raghavan M., Bonagura V.R., Morrison S.L., Bjorkman P.J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995, 34:14649-14657.
79. Reed R.K., Rubin K. Transcapillary exchange:role and imprtance of the interstitial fluid pressure and the extracellular matrix. Cardiovascular Research 2010, 87:211-217.
80. Resat H., Ewald J.A., Dixon D.A., Wiley H.S. An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophysical Journal 2003, 85:730-743.
81. Rippe B., Haraldsson B. Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiologica Scandinavica 1987, 131:411-428.
82. Rodewald R. pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. Journal of Cell Biology 1976, 71:666-669.
83. Rodewald R., Kraehenbuhl J.P. Receptor-mediated transport of IgG. Journal of Cell Biology 1984, 99:159s-164s.
84. Sanchez L.M., Penny D.M., Bjorkman P.J. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry 1999, 38:9471-9476.
85. Schnulle P.M., Hurley W.L. Sequence and expression of the FcRn in the porcine mammary gland. Veterinary Immunology and Immunopathology 2003, 91:227-231.
86. Shah D.K., Betts A.M. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of Pharmacokinetics and Pharmacodynamics 2012, 39:67-86.
87. Stapleton N.M., Andersen J.T., Stemerding A.M., Bjarnarson S.P., Verheul R.C., Gerritsen J., Zhao Y., Kleijer M., Sandlie I., de Haas M., Jonsdottir I., van der Schoot C.E., Vidarsson G. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nature Communications 2011, 2:599.
88. Supersaxo A., Hein W.R., Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharmaceutical Research 1990, 7:167-169.
89. Suzuki T., Ishii-Watabe A., Tada M., Kobayashi T., Kanayasu-Toyoda T., Kawanishi T., Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. Journal of Immunology 2010, 184:1968-1976.
90. Taraska J.W., Perrais D., Ohara-Imaizumi M., Nagamatsu S., Almers W. Secretory granules are recaptured largely intact after stimulated exocytosis in cultured endocrine cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2070-2075.
91. Tesar D.B., Bjorkman P.J. An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Current Opinion in Structural Biology 2010, 20:226-233.
92. Tesar D.B., Tiangco N.E., Bjorkman P.J. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 2006, 7:1127-1142.
93. Thornton C.A., Welle S., Griggs R.C., Abraham G.N. Human IgG production in vivo: determination of synthetic rate by nonradioactive tracer incorporation. Journal of Immunology 1996, 157:950-955.
94. Tsuboi T., Rutter G.A. Multiple forms of "kiss-and-run" exocytosis revealed by evanescent wave microscopy. Current Biology 2003, 13:563-567.
95. Tsuboi T., Zhao C., Terakawa S., Rutter G.A. Simultaneous evanescent wave imaging of insulin vesicle membrane and cargo during a single exocytotic event. Current Biology 2000, 10:1307-1310.
96. Tsuboi T., McMahon H.T., Rutter G.A. Mechanisms of dense core vesicle recapture following "kiss and run" ("cavicapture") exocytosis in insulin-secreting cells. The Journal of Biological Chemistry 2004, 279:47115-47124.
97. Urva S.R., Yang V.C., Balthasar J.P. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. Journal of Pharmaceutical Science 2010, 99:1582-1600.
98. Vaccaro C., Bawdon R., Wanjie S., Ober R.J., Ward E.S. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:18709-18714.
99. Vaughn D.E., Milburn C.M., Penny D.M., Martin W.L., Johnson J.L., Bjorkman P.J. Identification of critical IgG binding epitopes on the neonatal Fc receptor. Journal of Molecular Biology 1997, 274:597-607.
100. Vegh A., Farkas A., Kovesdi D., Papp K., Cervenak J., Schneider Z., Bender B., Hiripi L., Laszlo G., Prechl J., Matko J., Kacskovics I. FcRn overexpression in transgenic mice results in augmented APC activity and robust immune response with increased diversity of induced antibodies. PloS One 2012, 7:e36286.
101. Vugmeyster Y., Xu X., Theil F.P., Khawli L.A., Leach M.W. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World Journal of Biological Chemistry 2012, 3:73-92.
102. Waldmann T.A., Strober W. Metabolism of immunoglobulins. Progress in Allergy 1969, 13:1-110.
103. Waldmann T.A., Terry W.D. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. The Journal of clinical investigation 1990, 86:2093-2098.
104. Wallace K.H., Rees A.R. Studies on the immunoglobulin-G Fc-fragment receptor from neonatal rat small intestine. Biochemical Journal 1980, 188:9-16.
105. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics 2008, 84:548-558.
106. Wang W., Lu P., Fang Y., Hamuro L., Pittman T., Carr B., Hochman J., Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metabolism and Disposition 2011, 39:1469-1477.
107. Ward E.S., Zhou J., Ghetie V., Ober R.J. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. International Immunology 2003, 15:187-195.
108. Xiao J.J. Pharmacokinetic models for FcRn-mediated IgG disposition. Journal of Biomedicine and Biotechnology 2012, 2012:282989.
109. Yeung Y.A., Leabman M.K., Marvin J.S., Qiu J., Adams C.W., Lien S., Starovasnik M.A., Lowman H.B. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. Journal of Immunology 2009, 182:7663-7671.
110. Yeung Y.A., Wu X., Reyes A.E., 2nd, Vernes J.M., Lien S., Lowe J., Maia M., Forrest W.F., Meng Y.G., Damico L.A., Ferrara N., Lowman H.B. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Research 2010, 70:3269-3277.
111. Yoshida M., Claypool S.M., Wagner J.S., Mizoguchi E., Mizoguchi A., Roopenian D.C., Lencer W.I., Blumberg R.S. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004, 20:769-783.
112. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Nature Biotechnology 2010, 28:157-159.
113. Zheng Y., Scheerens H., Davis J.C., Deng R., Fischer S.K., Woods C., Fielder P.J., Stefanich E.G. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clinical Pharmacology and Therapeutics 2011, 89:283-290.
114. Zhu X., Meng G., Dickinson B.L., Li X., Mizoguchi E., Miao L., Wang Y., Robert C., Wu B., Smith P.D., Lencer W.I., Blumberg R.S. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. Journal of Immunology 2001, 166:3266-3276.
115. Zuckier L.S., Georgescu L., Chang C.J., Scharff M.D., Morrison S.L. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994, 73:794-799.
116. Zuckier L.S., Chang C.J., Scharff M.D., Morrison S.L. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Research 1998, 58:3905-3908.